martedì, 5 maggio 2026

Notizie AIOM – anno XVII

Olaparib Approved in Europe for BRCA+ Breast Cancer

April 10, 2019 - The European Commission has approved olaparib for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer. The decision is based on findings from the phase III OlympiAD trial, in which the ...
Leggi tutto

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

HER2 amplification is detected in 3% of patients with colorectal cancer (CRC), making tumors in the metastatic setting vulnerable to double pharmacological HER2 blockade. Preclinical findings show that it also might impair response to anti-epidermal growth factor receptor ...
Leggi tutto

The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients’ quality of life

Patient-reported outcomes (PROs) are the gold standard to describe subjective symptoms. Nurses can be successfully involved in collecting symptom information, because of their direct relationship with the patient. In order to improve clinical management of outpatients receiving ...
Leggi tutto

8 aprile 2019 – Nota Informativa Importante su medicinali contenenti fluorochinoloni

8 aprile 2019 – ECDC. Consultazione pubblica sulla Guida ai vaccini HPV

9 aprile 2019 – Chiusura Registri Ofatumumab (Novartis)

9 aprile 2019 – Modifica Registro OFEV

10 aprile 2019 – Chiusura Managed Entry Agreements (MEA) Registri Ofatumumab (Novartis)

11 aprile 2019 – Carenza Pegaspargasi (Servier) – modalità di richiesta d’Importazione dall’estero

American College of Physicians Issues Guidance Statement for Breast Cancer Screening in Average-Risk Women

April 9, 2019 - Average-risk women between the ages of 50 and 74 who have no symptoms for breast cancer should undergo breast cancer screening with mammography every other year, the American College of Physicians (ACP) has recommended in a new evidence-based guidance statement ...
Leggi tutto